{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:11:40Z","timestamp":1790975500734,"version":"4.1.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11010-024-05057-2","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T14:02:20Z","timestamp":1720101740000},"page":"1225-1239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers"],"prefix":"10.1007","volume":"480","author":[{"given":"Weiqin","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihemaitijiang","family":"Aihaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paziliya","family":"Abudukeranmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"issue":"7529","key":"5057_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/516S1a","volume":"516","author":"L Gravitz","year":"2014","unstructured":"Gravitz L (2014) Liver cancer. Nature 516(7529):S1","journal-title":"Nature"},{"issue":"1","key":"5057_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2017.0112","volume":"24","author":"BH Kim","year":"2018","unstructured":"Kim BH, Park JW (2018) Epidemiology of liver cancer in South Korea. Clin Mol Hepatol 24(1):1\u20139","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"5057_CR3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP (2021) Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol 18(7):493\u2013502","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"5057_CR4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel EM, Brand RE, Goggins M (2023) Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 164(5):752\u2013765","journal-title":"Gastroenterology"},{"issue":"1","key":"5057_CR5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","volume":"159","author":"M Arnold","year":"2020","unstructured":"Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F (2020) Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 159(1):335\u201349.e15","journal-title":"Gastroenterology"},{"key":"5057_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.027","volume":"520","author":"J Cai","year":"2021","unstructured":"Cai J, Chen H, Lu M, Zhang Y, Lu B, You L, Zhang T, Dai M, Zhao Y (2021) Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Lett 520:1","journal-title":"Cancer Lett"},{"issue":"1","key":"5057_CR7","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.jhep.2015.02.007","volume":"62","author":"J Bruix","year":"2015","unstructured":"Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V (2015) Liver cancer: approaching a personalized care. J Hepatol 62(1):S144\u2013S156","journal-title":"J Hepatol"},{"issue":"5","key":"5057_CR8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1136\/jmedgenet-2016-104171","volume":"54","author":"XY Zhang","year":"2017","unstructured":"Zhang XY, Zhang PY (2017) Gastric cancer: somatic genetics as a guide to therapy. J Med Genet 54(5):305\u2013312","journal-title":"J Med Genet"},{"issue":"2","key":"5057_CR9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1245\/s10434-020-09375-9","volume":"28","author":"S Alonso","year":"2021","unstructured":"Alonso S, Saltz L (2021) The landmark series: chemotherapy for non-metastatic colon cancer. Ann Surg Oncol 28(2):995\u20131001","journal-title":"Ann Surg Oncol"},{"key":"5057_CR10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/hel.12339","volume":"21","author":"M Venerito","year":"2016","unstructured":"Venerito M, Link A, Rokkas T, Malfertheiner P (2016) Gastric cancer\u2013clinical and epidemiological aspects. Helicobacter 21:39\u201344","journal-title":"Helicobacter"},{"issue":"11","key":"5057_CR11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/cac2.12220","volume":"41","author":"L Lu","year":"2021","unstructured":"Lu L, Mullins CS, Schafmayer C, Zei\u00dfig S, Linnebacher M (2021) A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors. Cancer Commun (Lond) 41(11):1137\u20131151","journal-title":"Cancer Commun (Lond)"},{"key":"5057_CR12","doi-asserted-by":"crossref","first-page":"1101324","DOI":"10.3389\/fimmu.2023.1101324","volume":"14","author":"K Chen","year":"2023","unstructured":"Chen K, Li Y, Wang B, Yan X, Tao Y, Song W, Xi Z, He K, Xia Q (2023) Patient-derived models facilitate precision medicine in liver cancer by remodeling cell-matrix interaction. Front Immunol 14:1101324","journal-title":"Front Immunol"},{"issue":"9791","key":"5057_CR13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreatic cancer. Lancet 378(9791):607\u2013620","journal-title":"Lancet"},{"issue":"3","key":"5057_CR14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3748\/wjg.v12.i3.354","volume":"12","author":"KD Crew","year":"2006","unstructured":"Crew KD, Neugut AI (2006) Epidemiology of gastric cancer. World J Gastroenterol 12(3):354\u2013362","journal-title":"World J Gastroenterol"},{"issue":"1","key":"5057_CR15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-022-01582-0","volume":"21","author":"C Xue","year":"2022","unstructured":"Xue C, Li G, Zheng Q, Gu X, Bao Z, Lu J, Li L (2022) The functional roles of the circRNA\/Wnt axis in cancer. Mol Cancer 21(1):108","journal-title":"Mol Cancer"},{"key":"5057_CR16","doi-asserted-by":"crossref","first-page":"216127","DOI":"10.1016\/j.canlet.2023.216127","volume":"560","author":"Y Chen","year":"2023","unstructured":"Chen Y, Chen T, Fang JY (2023) Burden of gastrointestinal cancers in China from 1990 to 2019 and projection through 2029. Cancer Lett 560:216127","journal-title":"Cancer Lett"},{"issue":"4","key":"5057_CR17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0091-7435(87)90064-8","volume":"16","author":"JC McGiff","year":"1987","unstructured":"McGiff JC (1987) Arachidonic acid metabolism. Prev Med 16(4):503\u2013509","journal-title":"Prev Med"},{"key":"5057_CR18","doi-asserted-by":"crossref","first-page":"108455","DOI":"10.1016\/j.pharmthera.2023.108455","volume":"248","author":"H Yang","year":"2023","unstructured":"Yang H, Rothenberger E, Zhao T, Fan W, Kelly A, Attaya A, Fan D, Panigrahy D, Deng J (2023) Regulation of inflammation in cancer by dietary eicosanoids. Pharmacol Ther 248:108455","journal-title":"Pharmacol Ther"},{"issue":"2","key":"5057_CR19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0955-0674(93)90116-8","volume":"5","author":"D Piomelli","year":"1993","unstructured":"Piomelli D (1993) Arachidonic acid in cell signaling. Curr Opin Cell Biol 5(2):274\u2013280","journal-title":"Curr Opin Cell Biol"},{"issue":"2\u20133","key":"5057_CR20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10555-018-9750-0","volume":"37","author":"AA Panagiotopoulos","year":"2018","unstructured":"Panagiotopoulos AA, Kalyvianaki K, Castanas E, Kampa M (2018) Eicosanoids in prostate cancer. Cancer Metastasis Rev 37(2\u20133):237\u2013243","journal-title":"Cancer Metastasis Rev"},{"key":"5057_CR21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pharmthera.2018.11.009","volume":"196","author":"LN Sausville","year":"2019","unstructured":"Sausville LN, Williams SM, Pozzi A (2019) Cytochrome P450 epoxygenases and cancer: A genetic and a molecular perspective. Pharmacol Ther 196:183\u201394","journal-title":"Pharmacol Ther"},{"key":"5057_CR22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/ijms18122661","volume":"18","author":"TF Borin","year":"2017","unstructured":"Borin TF, Angara K, Rashid MH, Achyut BR, Arbab AS (2017) Arachidonic acid metabolite as a novel therapeutic target in breast cancer metastasis. Int J Mol Sci 18:266","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5057_CR23","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.intimp.2009.02.003","volume":"9","author":"CA Hyde","year":"2009","unstructured":"Hyde CA, Missailidis S (2009) Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol 9(6):701\u2013715","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"5057_CR24","doi-asserted-by":"crossref","first-page":"e1483","DOI":"10.1002\/ctm2.1483","volume":"13","author":"X Li","year":"2023","unstructured":"Li X, Chen G, Wang F, Guo X, Zhang R, Liu P, Dong L, Yu W, Wang H, Wang H et al (2023) Oncogenic PIK3CA recruits myeloid-derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5-lipoxygenase-dependent arachidonic acid pathway. Clin Transl Med 13(11):e1483","journal-title":"Clin Transl Med"},{"key":"5057_CR25","doi-asserted-by":"crossref","first-page":"618501","DOI":"10.3389\/fimmu.2021.618501","volume":"12","author":"M Xu","year":"2021","unstructured":"Xu M, Wang X, Li Y, Geng X, Jia X, Zhang L, Yang H (2021) Arachidonic acid metabolism controls macrophage alternative activation through regulating oxidative phosphorylation in PPAR\u03b3 dependent manner. Front Immunol 12:618501","journal-title":"Front Immunol"},{"issue":"24","key":"5057_CR26","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1158\/0008-5472.CAN-21-4362","volume":"82","author":"P Pan","year":"2022","unstructured":"Pan P, Qin G, Wang B, Yu H, Chen J, Liu J, Bing K, Shen J, Ren D, Zhao Y et al (2022) HDAC5 loss enhances phospholipid-derived arachidonic acid generation and confers sensitivity to cPLA2 inhibition in pancreatic cancer. Cancer Res 82(24):4542\u20134554","journal-title":"Cancer Res"},{"issue":"2","key":"5057_CR27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/cas.16035","volume":"115","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Liu X, Xiang Y, Hou Z, He K, Zhong G, Hu J, Cai D, Liu Y, Ren J et al (2024) Inhibiting cholesterol de novo synthesis promotes hepatocellular carcinoma progression by upregulating prostaglandin E synthase 2-mediated arachidonic acid metabolism under high fatty acid conditions. Cancer Sci 115(2):477\u2013489","journal-title":"Cancer Sci"},{"issue":"1","key":"5057_CR28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, Bao Z, Lu J, Li L (2023) Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther 8(1):204","journal-title":"Signal Transduct Target Ther"},{"issue":"2\u20133","key":"5057_CR29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10555-018-9732-2","volume":"37","author":"J Hu","year":"2018","unstructured":"Hu J, Fr\u00f6mel T, Fleming I (2018) Angiogenesis and vascular stability in eicosanoids and cancer. Cancer Metastasis Rev 37(2\u20133):425\u2013438","journal-title":"Cancer Metastasis Rev"},{"issue":"1\u20132","key":"5057_CR30","first-page":"141","volume":"253","author":"R Jones","year":"2003","unstructured":"Jones R, Adel-Alvarez LA, Alvarez OR, Broaddus R, Das S (2003) Arachidonic acid and colorectal carcinogenesis. Mol Cell Biochem 253(1\u20132):141\u2013149","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"5057_CR31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cbin.12086","volume":"48","author":"K Wang","year":"2024","unstructured":"Wang K, Shi JH, Gao J, Sun Y, Wang Z, Shi X, Guo W, Jin Y, Zhang S (2024) Arachidonic acid metabolism CYP450 pathway is deregulated in hepatocellular carcinoma and associated with microvascular invasion. Cell Biol Int 48(1):31\u201345","journal-title":"Cell Biol Int"},{"issue":"1","key":"5057_CR32","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/s41467-023-37590-x","volume":"14","author":"C Xu","year":"2023","unstructured":"Xu C, Gu L, Hu L, Jiang C, Li Q, Sun L, Zhou H, Liu Y, Xue H, Li J et al (2023) FADS1-arachidonic acid axis enhances arachidonic acid metabolism by altering intestinal microecology in colorectal cancer. Nat Commun 14(1):2042","journal-title":"Nat Commun"},{"issue":"51","key":"5057_CR33","doi-asserted-by":"crossref","first-page":"32433","DOI":"10.1073\/pnas.2006828117","volume":"117","author":"JY Lee","year":"2020","unstructured":"Lee JY, Nam M, Son HY, Hyun K, Jang SY, Kim JW, Kim MW, Jung Y, Jang E, Yoon SJ et al (2020) Polyunsaturated fatty acid biosynthesis pathway determines ferroptosis sensitivity in gastric cancer. Proc Natl Acad Sci U S A 117(51):32433\u201332442","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"5057_CR34","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI13210","volume":"107","author":"AR Brash","year":"2001","unstructured":"Brash AR (2001) Arachidonic acid as a bioactive molecule. J Clin Invest 107(11):1339\u20131345","journal-title":"J Clin Invest"},{"issue":"5","key":"5057_CR35","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1046\/j.1523-1755.1999.00502.x","volume":"55","author":"KF Badr","year":"1999","unstructured":"Badr KF (1999) Arachidonic acid in cellular activation. Kidney Int 55(5):2070\u20132071","journal-title":"Kidney Int"},{"key":"5057_CR36","doi-asserted-by":"crossref","first-page":"12029","DOI":"10.3390\/ijms222112029","volume":"22","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Khan H, Xiao J, Cheang WS (2021) Effects of arachidonic acid metabolites on cardiovascular health and disease. Int J Mol Sci 22:12029","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5057_CR37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00018-002-8468-9","volume":"59","author":"D Nie","year":"2002","unstructured":"Nie D, Honn KV (2002) Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci 59(5):799\u2013807","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"5057_CR38","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/00003495-200767060-00001","volume":"67","author":"Z Liao","year":"2007","unstructured":"Liao Z, Mason KA, Milas L (2007) Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs 67(6):821\u2013845","journal-title":"Drugs"},{"issue":"4","key":"5057_CR39","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s12276-020-0412-2","volume":"52","author":"H Moon","year":"2020","unstructured":"Moon H, White AC, Borowsky AD (2020) New insights into the functions of Cox-2 in skin and esophageal malignancies. Exp Mol Med 52(4):538\u2013547","journal-title":"Exp Mol Med"},{"issue":"12","key":"5057_CR40","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1200\/JCO.2005.09.051","volume":"23","author":"JR Brown","year":"2005","unstructured":"Brown JR, DuBois RN (2005) COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23(12):2840\u20132855","journal-title":"J Clin Oncol"},{"issue":"8","key":"5057_CR41","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.32010","volume":"125","author":"GP Nagaraju","year":"2019","unstructured":"Nagaraju GP, El-Rayes BF (2019) Cyclooxygenase-2 in gastrointestinal malignancies. Cancer 125(8):1221\u20131227","journal-title":"Cancer"},{"issue":"5","key":"5057_CR42","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1002\/jcp.27411","volume":"234","author":"N Hashemi Goradel","year":"2019","unstructured":"Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K (2019) Cyclooxygenase-2 in cancer: a review. J Cell Physiol 234(5):5683\u20135699","journal-title":"J Cell Physiol"},{"issue":"1","key":"5057_CR43","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1186\/s12885-018-4753-3","volume":"18","author":"Q Li","year":"2018","unstructured":"Li Q, Ma C, Zhang Z, Chen S, Zhi W, Zhang L, Zhang G, Shi L, Cao F, Ma T (2018) Association between cyclooxygenase-2 (COX-2) 8473 T > C polymorphism and cancer risk: a meta-analysis and trial sequential analysis. BMC Cancer 18(1):847","journal-title":"BMC Cancer"},{"issue":"2","key":"5057_CR44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10787-009-8049-8","volume":"17","author":"RE Harris","year":"2009","unstructured":"Harris RE (2009) Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17(2):55\u201367","journal-title":"Inflammopharmacology"},{"key":"5057_CR45","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.redox.2017.01.016","volume":"11","author":"X Yang","year":"2017","unstructured":"Yang X, Xu Y, Wang T, Shu D, Guo P, Miskimins K, Qian SY (2017) Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells. Redox Biol 11:653\u201362","journal-title":"Redox Biol"},{"issue":"8","key":"5057_CR46","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3319","volume":"12","author":"HE Barker","year":"2012","unstructured":"Barker HE, Cox TR, Erler JT (2012) The rationale for targeting the LOX family in cancer. Nat Rev Cancer 12(8):540\u2013552","journal-title":"Nat Rev Cancer"},{"key":"5057_CR47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2017.07.012","volume":"33","author":"M Wan","year":"2017","unstructured":"Wan M, Tang X, Stsiapanava A, Haeggstr\u00f6m JZ (2017) Biosynthesis of leukotriene B(4). Semin Immunol 33:3\u201315","journal-title":"Semin Immunol"},{"issue":"1","key":"5057_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2018.01.061","volume":"517","author":"J Chang","year":"2019","unstructured":"Chang J, Tang N, Fang Q, Zhu K, Liu L, Xiong X, Zhu Z, Zhang B, Zhang M, Tao J (2019) Inhibition of COX-2 and 5-LOX regulates the progression of colorectal cancer by promoting PTEN and suppressing PI3K\/AKT pathway. Biochem Biophys Res Commun 517(1):1\u20137","journal-title":"Biochem Biophys Res Commun"},{"key":"5057_CR49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.critrevonc.2018.05.012","volume":"127","author":"N Merchant","year":"2018","unstructured":"Merchant N, Bhaskar L, Momin S, Sujatha P, Reddy ABM, Nagaraju GP (2018) 5-Lipoxygenase: its involvement in gastrointestinal malignancies. Crit Rev Oncol Hematol 127:50\u20135","journal-title":"Crit Rev Oncol Hematol"},{"issue":"16","key":"5057_CR50","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.3748\/wjg.14.2494","volume":"14","author":"B Zhang","year":"2008","unstructured":"Zhang B, Wang CL, Zhao WH, Lv M, Wang CY, Zhong WX, Zhou WY, Yu WS, Zhang Y, Li S (2008) Effect of 5-LOX\/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2. World J Gastroenterol 14(16):2494\u20132500","journal-title":"World J Gastroenterol"},{"issue":"4","key":"5057_CR51","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/carcin\/bgi012","volume":"26","author":"YN Ye","year":"2005","unstructured":"Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH (2005) Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 26(4):827\u2013834","journal-title":"Carcinogenesis"},{"issue":"3\u20134","key":"5057_CR52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10555-007-9098-3","volume":"26","author":"GP Pidgeon","year":"2007","unstructured":"Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O\u2019Byrne K, Nie D, Honn KV (2007) Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 26(3\u20134):503\u2013524","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"5057_CR53","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0891-5849(03)00387-3","volume":"35","author":"P B\u00e9cuwe","year":"2003","unstructured":"B\u00e9cuwe P, Bianchi A, Didelot C, Barberi-Heyob M, Dau\u00e7a M (2003) Arachidonic acid activates a functional AP-1 and an inactive NF-kappaB complex in human HepG2 hepatoma cells. Free Radic Biol Med 35(6):636\u2013647","journal-title":"Free Radic Biol Med"},{"key":"5057_CR54","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/1471-2407-14-458","volume":"14","author":"E Pomianowska","year":"2014","unstructured":"Pomianowska E, Schj\u00f8lberg AR, Clausen OP, Gladhaug IP (2014) COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis. BMC Cancer 14:458","journal-title":"BMC Cancer"},{"issue":"31","key":"5057_CR55","doi-asserted-by":"crossref","first-page":"10729","DOI":"10.3748\/wjg.v20.i31.10729","volume":"20","author":"LM Knab","year":"2014","unstructured":"Knab LM, Grippo PJ, Bentrem DJ (2014) Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase. World J Gastroenterol 20(31):10729\u201310739","journal-title":"World J Gastroenterol"},{"key":"5057_CR56","doi-asserted-by":"crossref","first-page":"114732","DOI":"10.1016\/j.bcp.2021.114732","volume":"192","author":"ML Alvarez","year":"2021","unstructured":"Alvarez ML, Lorenzetti F (2021) Role of eicosanoids in liver repair, regeneration and cancer. Biochem Pharmacol 192:114732","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"5057_CR57","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/jhep.2003.50380","volume":"38","author":"J Leng","year":"2003","unstructured":"Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T (2003) Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38(3):756\u2013768","journal-title":"Hepatology"},{"issue":"5","key":"5057_CR58","first-page":"1410","volume":"7","author":"SH Bae","year":"2001","unstructured":"Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, Ryu WS (2001) Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 7(5):1410\u20131418","journal-title":"Clin Cancer Res"},{"issue":"13","key":"5057_CR59","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1158\/1078-0432.CCR-17-2725","volume":"24","author":"XF Dong","year":"2018","unstructured":"Dong XF, Liu TQ, Zhi XT, Zou J, Zhong JT, Li T, Mo XL, Zhou W, Guo WW, Liu X et al (2018) COX-2\/PGE2 axis regulates HIF2\u03b1 activity to promote hepatocellular carcinoma hypoxic response and reduce the sensitivity of sorafenib treatment. Clin Cancer Res 24(13):3204\u20133216","journal-title":"Clin Cancer Res"},{"issue":"12","key":"5057_CR60","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41589-023-01391-6","volume":"19","author":"L Sun","year":"2023","unstructured":"Sun L, Suo C, Zhang T, Shen S, Gu X, Qiu S, Zhang P, Wei H, Ma W, Yan R et al (2023) ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism. Nat Chem Biol 19(12):1492\u20131503","journal-title":"Nat Chem Biol"},{"issue":"6","key":"5057_CR61","first-page":"1195","volume":"4","author":"XM Xu","year":"2011","unstructured":"Xu XM, Deng JJ, Yuan GJ, Yang F, Guo HT, Xiang M, Ge W, Wu YG (2011) 5-Lipoxygenase contributes to the progression of hepatocellular carcinoma. Mol Med Rep 4(6):1195\u20131200","journal-title":"Mol Med Rep"},{"issue":"3","key":"5057_CR62","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/aps.2010.5","volume":"31","author":"Q Wang","year":"2010","unstructured":"Wang Q, Zhang WY, Ye LH, Zhang XD (2010) A mutant of HBx (HBxDelta127) promotes hepatoma cell growth via sterol regulatory element binding protein 1c involving 5-lipoxygenase. Acta Pharmacol Sin 31(3):367\u2013374","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"5057_CR63","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.4049\/jimmunol.1700544","volume":"200","author":"T Nosaka","year":"2018","unstructured":"Nosaka T, Baba T, Tanabe Y, Sasaki S, Nishimura T, Imamura Y, Yurino H, Hashimoto S, Arita M, Nakamoto Y et al (2018) Alveolar macrophages drive hepatocellular carcinoma lung metastasis by generating leukotriene B(4). J Immunol 200(5):1839\u20131852","journal-title":"J Immunol"},{"issue":"1","key":"5057_CR64","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00262-020-02660-2","volume":"70","author":"J Arai","year":"2021","unstructured":"Arai J, Goto K, Otoyama Y, Nakajima Y, Sugiura I, Kajiwara A, Tojo M, Ichikawa Y, Uozumi S, Shimozuma Y et al (2021) Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding. Cancer Immunol Immunother 70(1):203\u2013213","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"5057_CR65","doi-asserted-by":"crossref","first-page":"15377","DOI":"10.18632\/oncotarget.14165","volume":"8","author":"D Zhang","year":"2017","unstructured":"Zhang D, Lou J, Zhang X, Zhang L, Wang F, Xu D, Niu N, Wang Y, Wu Y, Cui W (2017) Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation. Oncotarget 8(9):15377\u201315392","journal-title":"Oncotarget"},{"key":"5057_CR66","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejphar.2015.07.047","volume":"764","author":"YJ Jeon","year":"2015","unstructured":"Jeon YJ, Kim JS, Hwang GH, Wu Z, Han HJ, Park SH, Chang W, Kim LK, Lee YM, Liu KH et al (2015) Inhibition of cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death in hepatocellular carcinoma HepG2 cells. Eur J Pharmacol 764:480\u20138","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"5057_CR67","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s13046-019-1480-9","volume":"38","author":"F Yang","year":"2019","unstructured":"Yang F, Zhang Y, Ren H, Wang J, Shang L, Liu Y, Zhu W, Shi X (2019) Ischemia reperfusion injury promotes recurrence of hepatocellular carcinoma in fatty liver via ALOX12-12HETE-GPR31 signaling axis. J Exp Clin Cancer Res 38(1):489","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"5057_CR68","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/onc.2009.421","volume":"29","author":"D Wang","year":"2010","unstructured":"Wang D, Dubois RN (2010) The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29(6):781\u2013788","journal-title":"Oncogene"},{"key":"5057_CR69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-3-642-30331-9_2","volume":"191","author":"DA Dixon","year":"2013","unstructured":"Dixon DA, Blanco FF, Bruno A, Patrignani P (2013) Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res 191:7\u201337","journal-title":"Recent Results Cancer Res"},{"issue":"41","key":"5057_CR70","doi-asserted-by":"crossref","first-page":"11748","DOI":"10.3748\/wjg.v21.i41.11748","volume":"21","author":"S Tuncer","year":"2015","unstructured":"Tuncer S, Banerjee S (2015) Eicosanoid pathway in colorectal cancer: recent updates. World J Gastroenterol 21(41):11748\u201311766","journal-title":"World J Gastroenterol"},{"issue":"5","key":"5057_CR71","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4103\/sjg.SJG_502_18","volume":"25","author":"J Liu","year":"2019","unstructured":"Liu J, Huang C, Wang J, Huang L, Chen S (2019) COX-2\/C-MET\/KRAS status-based prognostic nomogram for colorectal cancer: a multicenter cohort study. Saudi J Gastroenterol 25(5):293\u2013301","journal-title":"Saudi J Gastroenterol"},{"issue":"15","key":"5057_CR72","doi-asserted-by":"crossref","first-page":"11570","DOI":"10.1021\/acs.jmedchem.1c00890","volume":"64","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Ghosh A, Connolly PJ, King P, Wilde T, Wang J, Dong Y, Li X, Liao D, Chen H et al (2021) Gut-restricted selective cyclooxygenase-2 (COX-2) inhibitors for chemoprevention of colorectal cancer. J Med Chem 64(15):11570\u201311596","journal-title":"J Med Chem"},{"issue":"3","key":"5057_CR73","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cmdc.201800685","volume":"14","author":"A Buzharevski","year":"2019","unstructured":"Buzharevski A, Paskas S, S\u00e1rosi MB, Laube M, L\u00f6nnecke P, Neumann W, Mijatovic S, Maksimovic-Ivanic D, Pietzsch J, Hey-Hawkins E (2019) Carboranyl analogues of celecoxib with potent cytostatic activity against human melanoma and colon cancer cell lines. ChemMedChem 14(3):315\u2013321","journal-title":"ChemMedChem"},{"issue":"8","key":"5057_CR74","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1158\/1055-9965.EPI-08-0167","volume":"17","author":"N Arber","year":"2008","unstructured":"Arber N (2008) Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiol Biomarkers Prev 17(8):1852\u20131857","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"5057_CR75","first-page":"115","volume":"55","author":"D Wang","year":"2006","unstructured":"Wang D, Dubois RN (2006) Prostaglandins and cancer Gut 55(1):115\u2013122","journal-title":"Prostaglandins and cancer Gut"},{"key":"5057_CR76","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000086629","volume":"69","author":"MG Backlund","year":"2005","unstructured":"Backlund MG, Mann JR, Dubois RN (2005) Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology 69:28\u201332","journal-title":"Oncology"},{"issue":"13","key":"5057_CR77","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1158\/0008-5472.CAN-06-0425","volume":"66","author":"A Kaidi","year":"2006","unstructured":"Kaidi A, Qualtrough D, Williams AC, Paraskeva C (2006) Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 66(13):6683\u20136691","journal-title":"Cancer Res"},{"issue":"8","key":"5057_CR78","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1091\/mbc.e08-09-0939","volume":"20","author":"DA Rodriguez","year":"2009","unstructured":"Rodriguez DA, Tapia JC, Fernandez JG, Torres VA, Mu\u00f1oz N, Galleguillos D, Leyton L, Quest AF (2009) Caveolin-1-mediated suppression of cyclooxygenase-2 via a beta-catenin-Tcf\/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression. Mol Biol Cell 20(8):2297\u20132310","journal-title":"Mol Biol Cell"},{"issue":"6","key":"5057_CR79","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/gutjnl-2022-327323","volume":"72","author":"R Gamez-Belmonte","year":"2023","unstructured":"Gamez-Belmonte R, Mahapatro M, Erkert L, Gonzalez-Acera M, Naschberger E, Yu Y, Tena-Garitaonaindia M, Patankar JV, Wagner Y, Podstawa E et al (2023) Epithelial presenilin-1 drives colorectal tumour growth by controlling EGFR-COX2 signalling. Gut 72(6):1155\u20131166","journal-title":"Gut"},{"issue":"5753","key":"5057_CR80","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.1116221","volume":"310","author":"MD Castellone","year":"2005","unstructured":"Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310(5753):1504\u20131510","journal-title":"Science"},{"issue":"6","key":"5057_CR81","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00262-007-0417-x","volume":"57","author":"S Yaqub","year":"2008","unstructured":"Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bj\u00f8rnbeth BA, Task\u00e9n K (2008) Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 57(6):813\u2013821","journal-title":"Cancer Immunol Immunother"},{"issue":"20","key":"5057_CR82","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1158\/1078-0432.CCR-07-4631","volume":"14","author":"LG Melstrom","year":"2008","unstructured":"Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M, Rao SM, Witt RC, Ternent CA, Talamonti MS et al (2008) Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res 14(20):6525\u20136530","journal-title":"Clin Cancer Res"},{"issue":"3\u20134","key":"5057_CR83","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10735-006-9050-9","volume":"37","author":"AE Enayetallah","year":"2006","unstructured":"Enayetallah AE, French RA, Grant DF (2006) Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. J Mol Histol 37(3\u20134):133\u2013141","journal-title":"J Mol Histol"},{"issue":"10","key":"5057_CR84","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/1535-7163.MCT-12-0342","volume":"11","author":"R Hill","year":"2012","unstructured":"Hill R, Li Y, Tran LM, Dry S, Calvopina JH, Garcia A, Kim C, Wang Y, Donahue TR, Herschman HR et al (2012) Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther 11(10):2127\u20132137","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"5057_CR85","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41598-017-00288-4","volume":"7","author":"H Hu","year":"2017","unstructured":"Hu H, Han T, Zhuo M, Wu LL, Yuan C, Wu L, Lei W, Jiao F, Wang LW (2017) Elevated COX-2 expression promotes angiogenesis through EGFR\/p38-MAPK\/Sp1-dependent signalling in pancreatic cancer. Sci Rep 7(1):470","journal-title":"Sci Rep"},{"issue":"5","key":"5057_CR86","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1158\/1078-0432.CCR-13-1664","volume":"20","author":"J Gong","year":"2014","unstructured":"Gong J, Xie J, Bedolla R, Rivas P, Chakravarthy D, Freeman JW, Reddick R, Kopetz S, Peterson A, Wang H et al (2014) Combined targeting of STAT3\/NF-\u03baB\/COX-2\/EP4 for effective management of pancreatic cancer. Clin Cancer Res 20(5):1259\u20131273","journal-title":"Clin Cancer Res"},{"key":"5057_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-4-27","author":"S Yoshida","year":"2005","unstructured":"Yoshida S, Ujiki M, Ding XZ, Pelham C, Talamonti MS, Bell RH Jr, Denham W, Adrian TE (2005) Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. Mol Cancer. https:\/\/doi.org\/10.1186\/1476-4598-4-27","journal-title":"Mol Cancer"},{"issue":"2","key":"5057_CR88","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3892\/or.2014.3650","volume":"33","author":"GX Zhou","year":"2015","unstructured":"Zhou GX, Ding XL, Wu SB, Zhang HF, Cao W, Qu LS, Zhang H (2015) Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells. Oncol Rep 33(2):661\u2013668","journal-title":"Oncol Rep"},{"issue":"2","key":"5057_CR89","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.plefa.2005.04.016","volume":"73","author":"JI Gregor","year":"2005","unstructured":"Gregor JI, Kilian M, Heukamp I, Kiewert C, Kristiansen G, Schimke I, Walz MK, Jacobi CA, Wenger FA (2005) Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster. Prostaglandins Leukot Essent Fatty Acids 73(2):89\u201397","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"5057_CR90","doi-asserted-by":"crossref","first-page":"1177604","DOI":"10.3389\/fimmu.2023.1177604","volume":"14","author":"A Zhang","year":"2023","unstructured":"Zhang A, Zou X, Yang S, Yang H, Ma Z, Li J (2023) Effect of NETs\/COX-2 pathway on immune microenvironment and metastasis in gastric cancer. Front Immunol 14:1177604","journal-title":"Front Immunol"},{"issue":"3\u20134","key":"5057_CR91","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10555-011-9312-1","volume":"30","author":"A Thiel","year":"2011","unstructured":"Thiel A, Mrena J, Ristim\u00e4ki A (2011) Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Rev 30(3\u20134):387\u2013395","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"5057_CR92","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1053\/j.gastro.2006.04.037","volume":"130","author":"JD Potter","year":"2006","unstructured":"Potter JD, Ulrich CM (2006) COX-2 and gastric cancer: More on inflammation and neoplasia. Gastroenterology 130(7):2198\u20132200","journal-title":"Gastroenterology"},{"issue":"2","key":"5057_CR93","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3892\/ijmm.2017.3011","volume":"40","author":"Y Ye","year":"2017","unstructured":"Ye Y, Liu M, Yuan H, Ning S, Wang Y, Chen Z, Ji R, Guo Q, Li Q, Zhou Y (2017) COX-2 regulates Snail expression in gastric cancer via the Notch1 signaling pathway. Int J Mol Med 40(2):512\u2013522","journal-title":"Int J Mol Med"},{"issue":"3","key":"5057_CR94","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/labinvest.3780243","volume":"81","author":"JW Lim","year":"2001","unstructured":"Lim JW, Kim H, Kim KH (2001) Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab Invest 81(3):349\u2013360","journal-title":"Lab Invest"},{"issue":"2","key":"5057_CR95","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/jgh.15184","volume":"36","author":"H Lin","year":"2021","unstructured":"Lin H, Weng J, Mei H, Zhuang M, Xiao X, Du F, Lin L, Wu J, Chen Z, Huang Y et al (2021) 5-Lipoxygenase promotes epithelial-mesenchymal transition through the ERK signaling pathway in gastric cancer. J Gastroenterol Hepatol 36(2):455\u2013466","journal-title":"J Gastroenterol Hepatol"},{"key":"5057_CR96","doi-asserted-by":"crossref","first-page":"1287570","DOI":"10.3389\/fchem.2023.1287570","volume":"11","author":"YQ Tian","year":"2023","unstructured":"Tian YQ, Liu J, Cheng P, Zou J, Xu HF, Shi XH, Zhang YS, Mei L (2023) Dual COX-2\/5-LOX inhibitors from zanthoxylum simulans inhibit gastric cancer cells by cross-mediating thyroid, estrogen, and oxytocin signaling pathways. Front Chem 11:1287570","journal-title":"Front Chem"},{"key":"5057_CR97","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.2147\/OTT.S134599","volume":"10","author":"Z Hu","year":"2017","unstructured":"Hu Z, Yang Y, Zhao Y, Huang Y (2017) The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis. Onco Targets Ther 10:2893\u2013901","journal-title":"Onco Targets Ther"},{"issue":"4","key":"5057_CR98","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.3892\/ol.2015.3624","volume":"10","author":"J Chen","year":"2015","unstructured":"Chen J, Wu F, Pei HL, Gu WD, Ning ZH, Shao YJ, Huang J (2015) Analysis of the correlation between P53 and Cox-2 expression and prognosis in esophageal cancer. Oncol Lett 10(4):2197\u20132203","journal-title":"Oncol Lett"},{"issue":"2","key":"5057_CR99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dote.12479","volume":"30","author":"Y Lin","year":"2017","unstructured":"Lin Y, Shen LY, Fu H, Dong B, Yang HL, Yan WP, Kang XZ, Dai L, Zhou HT, Yang YB et al (2017) P21, COX-2, and E-cadherin are potential prognostic factors for esophageal squamous cell carcinoma. Dis Esophagus 30(2):1\u201310","journal-title":"Dis Esophagus"},{"issue":"6","key":"5057_CR100","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/carcin\/bgi304","volume":"27","author":"H Zhi","year":"2006","unstructured":"Zhi H, Wang L, Zhang J, Zhou C, Ding F, Luo A, Wu M, Zhan Q, Liu Z (2006) Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis 27(6):1214\u20131221","journal-title":"Carcinogenesis"},{"issue":"1","key":"5057_CR101","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4143\/crt.2016.190","volume":"49","author":"IH Pun","year":"2017","unstructured":"Pun IH, Chan D, Chan SH, Chung PY, Zhou YY, Law S, Lam AK, Chui CH, Chan AS, Lam KH et al (2017) Anti-cancer Effects of a novel quinoline derivative 83b1 on human esophageal squamous cell carcinoma through down-regulation of COX-2 mRNA and PGE(2). Cancer Res Treat 49(1):219\u2013229","journal-title":"Cancer Res Treat"},{"issue":"1","key":"5057_CR102","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/gast.2003.50008","volume":"124","author":"DA Corley","year":"2003","unstructured":"Corley DA, Kerlikowske K, Verma R, Buffler P (2003) Protective association of aspirin\/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124(1):47\u201356","journal-title":"Gastroenterology"},{"issue":"19","key":"5057_CR103","doi-asserted-by":"crossref","first-page":"6703","DOI":"10.1158\/1078-0432.CCR-04-0838","volume":"10","author":"X Chen","year":"2004","unstructured":"Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, Beer DG, Giordano TJ, Lin Y, Shih WC et al (2004) Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 10(19):6703\u20136709","journal-title":"Clin Cancer Res"},{"issue":"4","key":"5057_CR104","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/carcin\/bgi026","volume":"26","author":"A Hoque","year":"2005","unstructured":"Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA, Xu XC (2005) Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 26(4):785\u2013791","journal-title":"Carcinogenesis"},{"issue":"1","key":"5057_CR105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2011.05.010","volume":"309","author":"HY Shi","year":"2011","unstructured":"Shi HY, Lv FJ, Zhu ST, Wang QG, Zhang ST (2011) Dual inhibition of 5-LOX and COX-2 suppresses esophageal squamous cell carcinoma. Cancer Lett 309(1):19\u201326","journal-title":"Cancer Lett"},{"issue":"3","key":"5057_CR106","doi-asserted-by":"crossref","first-page":"192","DOI":"10.17305\/bjbms.2010.2684","volume":"10","author":"M Legan","year":"2010","unstructured":"Legan M (2010) Cyclooxygenase-2, p53 and glucose transporter-1 as predictors of malignancy in the development of gallbladder carcinomas. Bosn J Basic Med Sci 10(3):192\u2013196","journal-title":"Bosn J Basic Med Sci"},{"issue":"2","key":"5057_CR107","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1054\/plef.1999.0011","volume":"60","author":"WE Longo","year":"1999","unstructured":"Longo WE, Panesar N, Mazuski JE, Kaminski D (1999) Synthetic pathways of gallbladder mucosal prostanoids: the role of cyclooxygenase-1 and 2. Prostaglandins Leukot Essent Fatty Acids 60(2):77\u201385","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"21","key":"5057_CR108","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.3748\/wjg.v12.i21.3425","volume":"12","author":"M Legan","year":"2006","unstructured":"Legan M, Luzar B, Marolt VF, Cor A (2006) Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions. World J Gastroenterol 12(21):3425\u20133429","journal-title":"World J Gastroenterol"},{"issue":"24","key":"5057_CR109","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.3748\/wjg.v11.i24.3724","volume":"11","author":"YH Zhi","year":"2005","unstructured":"Zhi YH, Liu RS, Song MM, Tian Y, Long J, Tu W, Guo RX (2005) Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol 11(24):3724\u20133728","journal-title":"World J Gastroenterol"},{"issue":"4","key":"5057_CR110","first-page":"1157","volume":"8","author":"T Asano","year":"2002","unstructured":"Asano T, Shoda J, Ueda T, Kawamoto T, Todoroki T, Shimonishi M, Tanabe T, Sugimoto Y, Ichikawa A, Mutoh M et al (2002) Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res 8(4):1157\u20131167","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5057_CR111","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4143\/crt.2005.37.3.171","volume":"37","author":"WS Moon","year":"2005","unstructured":"Moon WS, Park HS, Lee H, Pai R, Tarnawski AS, Kim KR, Jang KY (2005) Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer. Cancer Res Treat 37(3):171\u2013176","journal-title":"Cancer Res Treat"},{"issue":"3","key":"5057_CR112","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ijc.10222","volume":"98","author":"T Kawamoto","year":"2002","unstructured":"Kawamoto T, Shoda J, Asano T, Ueda T, Furukawa M, Koike N, Tanaka N, Todoroki T, Miwa M (2002) Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int J Cancer 98(3):427\u2013434","journal-title":"Int J Cancer"},{"issue":"1","key":"5057_CR113","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1186\/s12885-018-4575-3","volume":"18","author":"JM Nemunaitis","year":"2018","unstructured":"Nemunaitis JM, Brown-Glabeman U, Soares H, Belmonte J, Liem B, Nir I, Phuoc V, Gullapalli RR (2018) Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. BMC Cancer 18(1):665","journal-title":"BMC Cancer"},{"issue":"6","key":"5057_CR114","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3322\/canjclin.51.6.349","volume":"51","author":"EC Lazcano-Ponce","year":"2001","unstructured":"Lazcano-Ponce EC, Miquel JF, Mu\u00f1oz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G, Nervi F (2001) Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51(6):349\u2013364","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5057_CR115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","volume":"8","author":"JC Roa","year":"2022","unstructured":"Roa JC, Garc\u00eda P, Kapoor VK, Maithel SK, Javle M, Koshiol J (2022) Gallbladder cancer Nat Rev Dis Primers 8(1):69","journal-title":"Gallbladder cancer Nat Rev Dis Primers"},{"key":"5057_CR116","doi-asserted-by":"crossref","first-page":"104912","DOI":"10.1016\/j.tiv.2020.104912","volume":"67","author":"P Sharma","year":"2020","unstructured":"Sharma P, Caldwell TS, Rivera MN, Gullapalli RR (2020) Cadmium exposure activates Akt\/ERK signaling and pro-inflammatory COX-2 expression in human gallbladder epithelial cells via a ROS dependent mechanism. Toxicol In Vitro 67:104912","journal-title":"Toxicol In Vitro"},{"issue":"6","key":"5057_CR117","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1517\/14656566.5.6.1271","volume":"5","author":"IA Malik","year":"2004","unstructured":"Malik IA (2004) Gallbladder cancer: current status. Expert Opin Pharmacother 5(6):1271\u20131277","journal-title":"Expert Opin Pharmacother"},{"key":"5057_CR118","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/1535-7163.MCT-07-0015","volume":"6","author":"K Kiguchi","year":"2007","unstructured":"Kiguchi K, Ruffino L, Kawamoto T, Franco E, Kurakata S, Fujiwara K, Hanai M, Rumi M, DiGiovanni J (2007) Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice. Mol Cancer Ther 6:1709\u201317","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"5057_CR119","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.3892\/ol.2017.5914","volume":"13","author":"M Deng","year":"2017","unstructured":"Deng M, Qin Y, Chen X, Li D, Wang Q, Zheng H, Gu L, Deng C, Xue Y, Zhu D et al (2017) Combination of celecoxib and PD184161 exerts synergistic inhibitory effects on gallbladder cancer cell proliferation. Oncol Lett 13(5):3850\u20133858","journal-title":"Oncol Lett"},{"issue":"1","key":"5057_CR120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R (2022) Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer 21(1):47","journal-title":"Mol Cancer"},{"issue":"2","key":"5057_CR121","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41388-022-02537-x","volume":"42","author":"D Li","year":"2023","unstructured":"Li D, Wang Y, Dong C, Chen T, Dong A, Ren J, Li W, Shu G, Yang J, Shen W et al (2023) CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1. Oncogene 42(2):83\u201398","journal-title":"Oncogene"},{"issue":"1","key":"5057_CR122","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","volume":"12","author":"Y Mou","year":"2019","unstructured":"Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, Li B (2019) Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol 12(1):34","journal-title":"J Hematol Oncol"},{"issue":"5","key":"5057_CR123","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D (2021) Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol 18(5):280\u2013296","journal-title":"Nat Rev Clin Oncol"},{"key":"5057_CR124","first-page":"188848","volume":"1","author":"Y Huang","year":"1878","unstructured":"Huang Y, Wang S, Ke A (1878) Guo K (2023) Ferroptosis and its interaction with tumor immune microenvironment in liver cancer. Biochim Biophys Acta Rev Cancer 1:188848","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"5057_CR125","doi-asserted-by":"crossref","first-page":"116074","DOI":"10.1016\/j.biopha.2023.116074","volume":"170","author":"Z Wang","year":"2024","unstructured":"Wang Z, Zhou C, Zhang Y, Tian X, Wang H, Wu J, Jiang S (2024) From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma. Biomed Pharmacother 170:116074","journal-title":"Biomed Pharmacother"},{"key":"5057_CR126","doi-asserted-by":"crossref","first-page":"116183","DOI":"10.1016\/j.ejmech.2024.116183","volume":"267","author":"X Zhang","year":"2024","unstructured":"Zhang X, Chen Y, Li X, Xu H, Yang J, Wang C, Zhang C, Deng Y, Lu A, Zheng C et al (2024) Carrier-free self-assembled nanomedicine based on celastrol and galactose for targeting therapy of hepatocellular carcinoma via inducing ferroptosis. Eur J Med Chem 267:116183","journal-title":"Eur J Med Chem"},{"issue":"Pt 2","key":"5057_CR127","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.jcis.2021.09.049","volume":"607","author":"H Tian","year":"2022","unstructured":"Tian H, Zhao S, Nice EC, Huang C, He W, Zou B, Lin J (2022) A cascaded copper-based nanocatalyst by modulating glutathione and cyclooxygenase-2 for hepatocellular carcinoma therapy. J Colloid Interface Sci 607(Pt 2):1516\u20131526","journal-title":"J Colloid Interface Sci"},{"issue":"7","key":"5057_CR128","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1007\/s00210-023-02916-5","volume":"397","author":"Y Yang","year":"2024","unstructured":"Yang Y, Liu C, Wang M, Cheng H, Wu H, Luo S, Zhang M, Duan X, Li Q (2024) Arenobufagin regulates the p62-Keap1-Nrf2 pathway to induce autophagy-dependent ferroptosis in HepG2 cells. Naunyn Schmiedebergs Arch Pharmacol 397(7):4895\u20134909","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"5057_CR129","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Vanden Berghe T (2019) Targeting Ferroptosis to Iron Out Cancer. Cancer Cell 35(6):830\u2013849","journal-title":"Cancer Cell"},{"issue":"51","key":"5057_CR130","doi-asserted-by":"crossref","first-page":"e1904197","DOI":"10.1002\/adma.201904197","volume":"31","author":"C Liang","year":"2019","unstructured":"Liang C, Zhang X, Yang M, Dong X (2019) Recent Progress in Ferroptosis Inducers for Cancer Therapy. Adv Mater 31(51):e1904197","journal-title":"Adv Mater"},{"issue":"1","key":"5057_CR131","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13045-022-01392-3","volume":"15","author":"X Tong","year":"2022","unstructured":"Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B, Liu J, Yu X, Shi S (2022) Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol 15(1):174","journal-title":"J Hematol Oncol"},{"key":"5057_CR132","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0378-4274(98)00057-5","volume":"96\u201397","author":"F Marks","year":"1998","unstructured":"Marks F, F\u00fcrstenberger G, M\u00fcller-Decker K (1998) Arachidonic acid metabolism as a reporter of skin irritancy and target of cancer chemoprevention. Toxicol Lett 96\u201397:111\u20138","journal-title":"Toxicol Lett"},{"issue":"21","key":"5057_CR133","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1056\/NEJMoa067208","volume":"356","author":"AT Chan","year":"2007","unstructured":"Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356(21):2131\u20132142","journal-title":"N Engl J Med"},{"issue":"21","key":"5057_CR134","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMe078044","volume":"356","author":"SD Markowitz","year":"2007","unstructured":"Markowitz SD (2007) Aspirin and colon cancer\u2013targeting prevention? N Engl J Med 356(21):2195\u20132198","journal-title":"N Engl J Med"},{"issue":"2","key":"5057_CR135","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12282-016-0723-2","volume":"24","author":"S Gautam","year":"2017","unstructured":"Gautam S, Roy S, Ansari MN, Saeedan AS, Saraf SA, Kaithwas G (2017) DuCLOX-2\/5 inhibition: a promising target for cancer chemoprevention. Breast Cancer 24(2):180\u2013190","journal-title":"Breast Cancer"},{"key":"5057_CR136","doi-asserted-by":"crossref","first-page":"105171","DOI":"10.1016\/j.bioorg.2021.105171","volume":"115","author":"MMM El-Miligy","year":"2021","unstructured":"El-Miligy MMM, Al-Kubeisi AK, El-Zemity SR, Nassra RA, Abu-Serie MM, Hazzaa AA (2021) Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes. Bioorg Chem 115:105171","journal-title":"Bioorg Chem"},{"issue":"9","key":"5057_CR137","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/abbs\/gmt064","volume":"45","author":"K Bishayee","year":"2013","unstructured":"Bishayee K, Khuda-Bukhsh AR (2013) 5-lipoxygenase antagonist therapy: a new approach towards targeted cancer chemotherapy. Acta Biochim Biophys Sin (Shanghai) 45(9):709\u2013719","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"31","key":"5057_CR138","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.2174\/1381612826666210101153216","volume":"27","author":"P Vishnupriya","year":"2021","unstructured":"Vishnupriya P, Aparna A, Viswanadha VP (2021) Lipoxygenase (LOX) Pathway: a promising target to combat cancer. Curr Pharm Des 27(31):3349\u20133369","journal-title":"Curr Pharm Des"},{"issue":"22","key":"5057_CR139","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.2174\/092986712801661112","volume":"19","author":"P Aparoy","year":"2012","unstructured":"Aparoy P, Reddy KK, Reddanna P (2012) Structure and ligand based drug design strategies in the development of novel 5- LOX inhibitors. Curr Med Chem 19(22):3763\u20133778","journal-title":"Curr Med Chem"},{"issue":"7","key":"5057_CR140","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.biopha.2011.06.009","volume":"65","author":"X Ding","year":"2011","unstructured":"Ding X, Zhu C, Qiang H, Zhou X, Zhou G (2011) Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors. Biomed Pharmacother 65(7):486\u2013490","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"5057_CR141","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/carcin\/bgm265","volume":"29","author":"S Tavolari","year":"2008","unstructured":"Tavolari S, Bonaf\u00e8 M, Marini M, Ferreri C, Bartolini G, Brighenti E, Manara S, Tomasi V, Laufer S, Guarnieri T (2008) Licofelone, a dual COX\/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 29(2):371\u2013380","journal-title":"Carcinogenesis"},{"issue":"9","key":"5057_CR142","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2174\/0929867024606713","volume":"9","author":"X Leval","year":"2002","unstructured":"Leval X, Julemont F, Delarge J, Pirotte B, Dogne JM (2002) New trends in dual 5-LOX\/COX inhibition. Curr Med Chem 9(9):941\u2013962","journal-title":"Curr Med Chem"},{"issue":"4","key":"5057_CR143","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10555-010-9264-x","volume":"29","author":"D Panigrahy","year":"2010","unstructured":"Panigrahy D, Kaipainen A, Greene ER, Huang S (2010) Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev 29(4):723\u2013735","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"5057_CR144","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.pharmthera.2009.12.002","volume":"125","author":"BN Zordoky","year":"2010","unstructured":"Zordoky BN, El-Kadi AO (2010) Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 125(3):446\u2013463","journal-title":"Pharmacol Ther"},{"key":"5057_CR145","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/biom11071049","volume":"11","author":"C Sobolewski","year":"2021","unstructured":"Sobolewski C, Legrand N (2021) Celecoxib analogues for cancer treatment: an update on OSU-03012 and 2,5-Dimethyl-celecoxib. Biomolecules 11:1049","journal-title":"Biomolecules"},{"key":"5057_CR146","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semcancer.2016.02.001","volume":"40\u201341","author":"NS Yarla","year":"2016","unstructured":"Yarla NS, Bishayee A, Sethi G, Reddanna P, Kalle AM, Dhananjaya BL, Dowluru KS, Chintala R, Duddukuri GR (2016) Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Semin Cancer Biol 40\u201341:48\u201381","journal-title":"Semin Cancer Biol"},{"key":"5057_CR147","doi-asserted-by":"crossref","first-page":"110389","DOI":"10.1016\/j.biopha.2020.110389","volume":"129","author":"S Li","year":"2020","unstructured":"Li S, Jiang M, Wang L, Yu S (2020) Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement. Biomed Pharmacother 129:110389","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"5057_CR148","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1158\/1078-0432.CCR-09-0788","volume":"16","author":"DG Menter","year":"2010","unstructured":"Menter DG, Schilsky RL, DuBois RN (2010) Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 16(5):1384\u20131390","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5057_CR149","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1053\/j.gastro.2016.07.030","volume":"151","author":"Y Cao","year":"2016","unstructured":"Cao Y, Nishihara R, Qian ZR, Song M, Mima K, Inamura K, Nowak JA, Drew DA, Lochhead P, Nosho K et al (2016) Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes. Gastroenterology 151(5):879\u201392.e4","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"5057_CR150","doi-asserted-by":"crossref","first-page":"e530s","DOI":"10.6061\/clinics\/2018\/e530s","volume":"73","author":"RN Gomes","year":"2018","unstructured":"Gomes RN, Felipe da Costa S, Colquhoun A (2018) Eicosanoids and cancer. Clinics (Sao Paulo) 73(suppl 1):e530s","journal-title":"Clinics (Sao Paulo)"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05057-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-024-05057-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05057-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T14:17:00Z","timestamp":1739888220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-024-05057-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":150,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["5057"],"URL":"https:\/\/doi.org\/10.1007\/s11010-024-05057-2","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}